ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women

Citation
Sumner, Anne E, Jeremy D Furtado, Amber B Courville, Madia Ricks, Novie Younger-Coleman, Marshall K Tulloch-Reid, and Frank M Sacks. 2013. “ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women.” Nutrition & Metabolism 10 (1): 73. doi:10.1186/1743-7075-10-73. http://dx.doi.org/10.1186/1743-7075-10-73.

Published Version
doi:10.1186/1743-7075-10-73

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879518

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
ApoC-III and visceral adipose tissue contribute to paradoxically normal triglyceride levels in insulin-resistant African-American women

Anne E Sumner1*, Jeremy D Furtado2, Amber B Courville3, Madia Ricks1, Novie Younger-Coleman4, Marshall K Tulloch-Reid4 and Frank M Sacks2

Abstract

Background: African-Americans are more insulin-resistant than whites but have lower triglyceride (TG) concentrations. The metabolic basis for this is unknown. Our goal was to determine in a cross-sectional study the effect of insulin resistance, visceral adipose tissue (VAT) and the apolipoproteins, B, C-III and E, on race differences in TG content of very low density lipoproteins (VLDL).

Methods: The participants were 31 women (16 African-American, 15 white) of similar age (37 ± 9 vs. 38 ± 11y (mean ± SD), \(P=0.72\)) and BMI (32.4 ± 7.2 vs. 29.3 ± 6.0 kg/m², \(P=0.21\)). A standard diet (33% fat, 52% carbohydrate, 15% protein) was given for 7 days followed by a test meal (40% fat, 40% carbohydrate, 20% protein) on Day 8. Insulin sensitivity index (SI) was calculated from the minimal model. VAT was measured at L2-3. The influence of race, SI, VAT and apolipoproteins on the TG content of VLDL was determined by random effects models (REM).

Results: African-Americans were more insulin-resistant (SI: 3.6 ± 1.3 vs. 5.6 ± 2.6 mU/L⁻¹.min⁻¹, \(P<0.01\)) with less VAT (75 ± 59 vs. 102 ± 71 cm², \(P<0.01\)). TG, apoB and apoC-III content of light and dense VLDL were lower in African-Americans (all \(P<0.05\) except for apoC-III in light VLDL, \(P=0.11\)). ApoE content did not vary by race. In REM, VAT but not SI influenced the TG concentration of VLDL. In models with race, SI, VAT and all apolipoproteins entered, race was not significant but apoC-III and VAT remained significant determinants of TG concentration in light and dense VLDL.

Conclusions: Low concentrations of apoC-III and VAT in African-Americans contribute to race differences in TG concentrations.

Trial registration: ClinicalTrials.gov Identifier: NCT00484861

Keywords: ApoC-III, Visceral adipose tissue, Triglyceride, Apolipoprotein C-III, Visceral adiposity, Insulin resistance, African-Americans, Health disparities

Background

Triglyceride-based screening programs for cardiometabolic risk such as Metabolic Syndrome and Hypertriglyceridemic Waist are based on the principle that insulin resistance is a fundamental cause of diabetes and cardiovascular disease [1,2]. Their key premise is that triglyceride (TG) concentrations and visceral adiposity are excellent markers of insulin resistance. However, even though the prevalence of cardiometabolic disease is higher in African-Americans than whites, TG concentrations are lower in African-Americans [3]. Therefore these screening programs often fail to detect risk in African-Americans [4-6]. As African-American women have lower TG concentrations than African-American men, this racial disparity in the efficacy of screening tests is even more apparent in African-American women [7]. It is unknown why TG concentrations are not usually elevated in insulin-resistant African-American women. The influence

* Correspondence: AnneS@intra.niddk.nih.gov
1Diabetes, Endocrinology and Obesity Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
Full list of author information is available at the end of the article
ame of the apolipoproteins, apoB, apoC-III and apoE on TG concentrations in African-Americans is a potentially important but relatively unexplored area [8,9].

Insulin resistance is considered a key factor linking TG concentrations to visceral adipose tissue (VAT) [10,11]. As VAT is resistant to the anti-lipolytic effect of insulin, free fatty acid (FFA) release is increased when the VAT depot is enlarged. FFA from VAT is used in the synthesis of TG-rich very low density lipoproteins (VLDL). However, the metabolic sequence of expanded VAT, insulin resistance and hypertriglyceridemia may not be applicable to African-American women. African-American women are more insulin-resistant than white women but have less VAT [12]. Therefore, the balance between the opposing effects of insulin resistance and low VAT on TG levels awaits clarification.

In the fasting state, TG concentration is mostly a measure of the TG content of VLDL. VLDL represents a range of particles that vary in density. While both light and dense VLDL are secreted by the liver, light VLDL may undergo conversion to dense VLDL [13]. Postprandially, TG concentration represents a combination of light and dense VLDL as well as chylomicrons which are TG-rich particles secreted by the intestine [13]. VLDL particles are either cleared by the liver or converted sequentially to intermediate density lipoproteins (IDL) and low density lipoproteins (LDL) [13].

Each VLDL, IDL and LDL particle has a single apoB protein. But, apoC-III and apoE are present on some, but not all lipid particles [14-16]. ApoC-III promotes hypertriglyceridemia by interfering with hepatic clearance of VLDL [17,18]. In addition, the apoC-III gene has an insulin response element which negatively influences gene expression [19-21]. Hence insulin resistance may promote hypertriglyceridemia by altering apoC-III production. In contrast to apoC-III, apoE promotes hepatic clearance of VLDL and therefore, might help lower TG concentration.

It is challenging to distinguish the independent effects of insulin resistance, VAT and apolipoproteins on VLDL-TG. A strategy that simultaneously evaluates these factors has the potential to elucidate the influence of each on TG concentrations. Our goal was to compare the effect of insulin resistance, VAT and apoB, apoC-III and apoE on TG levels in light and dense VLDL in African-American and white women.

**Methods**

The study was designed to minimize the confounding effects of age, obesity and diet. Therefore African-American and white women of similar age and BMI were enrolled. In addition, for one week prior to the test meal, participants consumed the same diet.

**Subjects**

Recruitment was by flyers, newspaper advertisements and website. To enroll women had to be 18 to 64 years old, initiate a call to the study line, self-identify as healthy and deny a history of diabetes and use of medications, vitamins or food supplements which affect either glucose or lipid metabolism. An absence of anemia, liver, kidney or thyroid dysfunction was confirmed by routine blood tests at the screening visit. Overall, 35 women attended screening visits but one white woman was excluded because of the ingestion of fish oil. Thirty-four non-diabetic women (17 African-American and 17 whites) were enrolled. Following enrollment, one white woman became pregnant. In addition, samples from 2 women, 1 African-American and 1 white, could not be analyzed due to sample loss from a lab accident. The final cohort was 31 women (16 African-American, age and BMI range 24 to 53 years and 20.6 to 45.9 kg/m², respectively, and 15 white, age and BMI range 20 to 49 years and 21.5 to 38.6 kg/m², respectively). The study was approved by the NIDDK Institutional Review Board. All participants gave informed consent.

**Protocol**

The study was designed to be completed within 1 month or less.

At the screening visit a medical history, physical examination, blood work and an EKG were performed.

At the second visit an insulin-modified frequently sampled intravenous glucose tolerance test (IM-FSIGT) was performed [22]. After a 12 hour overnight fast the participant came to the Clinical Center at 7 AM. Intravenous catheters were placed in each antecubital vein. Dextrose (0.3 g/kg) was administered intravenously over 1 minute. An insulin (0.03 U/kg) bolus was injected at 20 min. Blood samples were taken at -10, -1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, 180 min. Glucose and insulin concentrations were entered into the minimal model and the insulin sensitivity index (S_i) (MinMOD Millenium v.6.02) calculated [23]. Acute insulin response to glucose (AIRg) was determined by the area under the insulin curve between 0 and 10 min for the insulin concentration above basal [23]. FFA were modeled mathematically as previously reported [12].

**Standard diet and test meal**

During the 7 day dietary period, all meals were prepared in the metabolic kitchen. On weekdays, participants reported to the Clinical Center to be weighed and eat breakfast. All other meals were provided in a cooler for consumption off-site. Compliance with picking up daily food packets and weekend food cooler was 100%.

On day 8, the participant came to the Clinical Center at 7 AM after a 12 hour fast. The test meal was consumed.
Blood samples were obtained fasting and 2, 4 and 6 hours postprandially.

**Standard diet**

The Mifflin St. Jeor equation multiplied by a physical activity factor was used to estimate energy needs [24,25]. The physical activity factor was based on a dietitian initiated interview and the National Research Council Dietary Reference Intake scale [24]. An activity factor of 1.00-1.39 is for sedentary activity; 1.40-1.59 for sedentary activity plus 30-60 min of moderate activity; 1.60-1.89 for sedentary activity plus >60 min of daily moderate activity; and 1.90-2.50 for sedentary activity plus >60 min of daily moderate activity and >60 min of vigorous activity or >120 min of moderate activity.

The macronutrient distribution of the meals was based on the typical American diet (33% fat, 52% carbohydrate, 15% protein) [26]. Energy content was adjusted by the dietitian for weight fluctuations of 1.5 kg from baseline [27]. Mean weight change for participants between Day 1 and Day 7 of the diet was $-0.67 \pm 0.98$ kg with no difference by race ($P = 0.533$).

**Standardized meal**

The meal on Day 8 consisted of 30% of the energy consumed on Day 7. The meal was an egg omelet with cheddar cheese and butter, plain bagel with cream cheese and orange juice (40% fat, 40% carbohydrate, 20% protein). Two white participants required cheese and orange juice which would have been required for their meal, the macronutrient distribution was conserved but applesauce added.

**Body composition**

VAT and subcutaneous adipose tissue (SAT) were measured at L2-3 using a GE HiSpeed Advantage CT/I scanner (Milwaukee, WI) and analyzed on a SUN workstation (MEDx image, Sensor System, Inc., Sterling, VA) [28]. Percent body fat was determined with a dual-energy X-ray absorptiometry (DXA) scan (Hologic QDR 4500A, Bedford, MA).

**Analytic measures**

Glucose was determined by the glucose oxidase method (Yellow Springs Instrument, Yellow Springs, Ohio). Intra-assay and inter-assay coefficients of variation were 1.5% and 2.5%. Insulin was measured with double antibody chemiluminescent sandwich assays (Diagnostic Products, Los Angeles, California). Intra-assay and inter-assay coefficients of variation were 1.1% and 4.3%. Lipid particle number and size was determined by NMR spectroscopy (LipoScience, Raleigh, NC).

**Ultracentrifugation**

Whole plasma samples were separated into density fractions by ultracentrifugation. Light VLDL was isolated by overlaying 700 μL of sample with 300 μL of $d = 1.006$ g/mL phosphate buffered saline aqueous solution (PBS) (Sigma-Aldrich St. Louis, MO) and spinning at 92,470 × g for 60 min at 15°C in the outer-most row of a Beckman 25-Ti rotor with a Beckman L8-70 M ultracentrifuge (Fullerton, CA). Top 200 ± 10 μL from each tube was collected by aspiration for analysis. Volume of sample was restored to 1 mL with PBS and the sample mixed by inversion prior to spinning again at the same conditions for 16 h. The top 200 ± 10 μL containing the dense VLDL was collected by aspiration for analysis. IDL was isolated by increasing the density of the sample to 1.025 g/mL. Plasma remaining after VLDL aspiration was returned to 800 μL with PBS, and 193 μL of 13% KBr and 7 μL of H2O were added followed by mixing by repeated inversion. Samples were spun for 16 h under the same conditions as for VLDL isolation and 200 ± 10 μL was aspirated. LDL was isolated by increasing the density of the sample to 1.063 g/mL. Plasma remaining after VLDL aspiration was returned to 800 μL with PBS, and 135 μL of 34% KBr and 65 μL of H2O were added followed by mixing by repeated inversion. Samples were spun for 24 h under the same conditions as for VLDL isolation and 300 ± 10 μL was aspirated. Four density fractions of plasma were analyzed: light VLDL ($d < 1.006$ g/mL, Svedberg units of flotation (Sf) 60 – 400), dense VLDL ($d < 1.006$ g/mL, Sf: 20 – 60), IDL ($1.006 \leq d < 1.025$ g/mL) and LDL ($1.025 \geq d < 1.063$ g/mL).

**Lipids and apolipoproteins**

Sandwich ELISA procedures using affinity-purified antibodies (Academy Biomedical Company, Inc., Houston, TX) were performed to determine apoB, apoC-III, and apoE concentrations in whole plasma and lipoprotein fractions. Cholesterol and TG were determined enzymatically (Thermo Scientific, Waltham, MA). Liquid transfer for 96-well plate loading and ELISA dilutions were handled robotically with Multiprobe II (Perkin Elmer, Waltham, MA). ELISA and lipid plates were read with a BioTek ELx808iu 96-well plate reader controlled by KCJunior software (BioTek, Winooski, VT). All assays were completed in triplicate. For apolipoproteins in lipoprotein subfractions, intra-assay and inter-assay variations were 5% and 18%; and for TG and cholesterol intra-assay and inter-assay variation were 3% to 4% and 12% to 17%, respectively.

**Statistical analyses**

Unless stated otherwise, data are presented as mean ± SD. P-values ≤0.05 were considered significant. Differences by race were determined with two-tailed unpaired t-test for continuous variables with a normal distribution and
Mann–Whitney U test for skewed. Dichotomous variable comparisons were by chi-square.

Generalized least squares random effects models (REM) were used to examine race differences in the lipid response to the meal using measurements from samples collected both fasting and postprandially. Response variables (TG fractions) were log transformed to improve model fit. Breusch and Pagan Lagrangian multiplier test for REM and a chi-square test for normality were used to determine whether error terms from the models satisfied the assumptions for REM. All models included race and time as a categorical variable. Models were built by adding SI and VAT singly and then in combination and their effect on the coefficient for race examined. ApoB, apoC-III and apo E were then added singly and in combination to a base model consisting of race, time, SI and VAT as explanatory variables, to determine if they were mediators of the relationship between race and TG.

Analyses were performed with STATA, v12.0 (College Station, Texas).

**Results**

Demographic and metabolic characteristics of the participants are provided in Table 1. By design, the women were similar in age and BMI. There was no difference by race in percent fat, or waist circumference (WC). However, peripheral fat, specifically, thigh circumference was higher in African-Americans. Adjusting for BMI, African-Americans had lower VAT but SAT did not differ by race.

In addition, African-Americans were more insulin-resistant (lower SI) and hyperinsulinemic (higher AIRg) than whites.

Demographic variables such as family history of diabetes, median income, education and smoking did not differ by race. Even though alcohol intake did not differ by race, no alcohol was allowed for the 7 days prior to the test meal.

**Effect of the standard diet on TG concentrations**

TG concentrations in both the African-American and white women declined on the controlled-nutrient diet, but the race difference remained constant (Figure 1). Day 1 of the diet, fasting TG concentrations in the African-American and white women were: 70 ± 47 vs. 112 ± 60, \( P = 0.041 \). After 7 days on the diet, fasting TG concentrations for the African-American and white women were: 62 ± 39 vs. 96 ± 45, \( P = 0.031 \).

**Test meal**

*Fasting Lipids and Apolipoproteins*

In whole plasma, levels of total cholesterol and LDL-cholesterol did not differ by race but TG was lower and HDL-cholesterol higher in African-Americans (Table 2). TG levels were lower in light and dense VLDL in African-Americans than whites, but did not differ in IDL or LDL. ApoB concentration of light and dense VLDL was lower in African-Americans than whites, but only reached significance in dense VLDL (\( P = 0.010 \)). ApoC-III in dense VLDL was lower in African-Americans (\( P = 0.014 \), but apoC-III

### Table 1 Demographic and metabolic characteristics of participants

| Variable                        | African-Americans (n = 16) | Whites (n = 15) | P-Value<sup>2</sup> |
|--------------------------------|----------------------------|----------------|---------------------|
| Age (y)                        | 37 ± 9                     | 38 ± 11        | 0.721               |
| BMI (kg/m²)                    | 32.4 ± 7.2                 | 29.3 ± 6.0     | 0.208               |
| Percent fat (%)                | 38.1 ± 8.3                 | 37.7 ± 7.8     | 0.892               |
| Waist circumference (cm)       | 98 ± 17                    | 100 ± 16       | 0.785               |
| Thigh circumference (cm)       | 65 ± 10                    | 55 ± 7         | 0.005               |
| VAT (cm²)³                     | 75 ± 59                    | 102 ± 71       | 0.002               |
| SAT (cm²)³                     | 311 ± 188                  | 256 ± 148      | 0.569               |
| SI (mU/L·min⁻¹)⁴              | 3.6 ± 1.3                  | 5.6 ± 2.6      | 0.009               |
| AIRg (mU/L·min⁻¹)⁵            | 661 ± 383                  | 224 ± 190      | <0.001              |
| Family history of diabetes    | 44%                        | 47%            | 0.870               |
| Median income                  | 555,000                    | 555,000        | 0.819               |
| No college degree              | 37%                        | 13%            | 0.124               |
| Graduate school                | 38%                        | 47%            | 0.605               |
| Smokers                        | 0/16                       | 2/15           | 0.311               |

<sup>1</sup>Data presented as mean ± SD.

<sup>2</sup>Continuous variables compared by unpaired t-tests, dichotomous by chi-square.

<sup>3</sup>P-value adjusted for BMI with regression analyses.

<sup>4</sup>SI: Insulin sensitivity index.

<sup>5</sup>AIRg: Acute Insulin Response to glucose.
did not differ by race in light VLDL, IDL or LDL. ApoE did not differ by race in any of the lipoproteins. In addition, LDL size (21.48 ± 0.70 vs. 21.29 ± 0.66 nm, \( P = 0.449 \)) and particle number did not differ by race (945 ± 307 vs. 1148 ± 345 nmol/L, \( P = 0.175 \)).

**TG, ApoB, ApoCIII and ApoE concentration during the test meal** In Figure 2 the TG and apolipoprotein concentration of each of the lipoproteins are presented at baseline and 2, 4 and 6 h postprandially. The TG concentration of light and dense VLDL was lower in African-Americans than whites but did not differ in IDL or LDL (Figure 2: First Row). Similarly, the apoB concentration in light and dense VLDL was lower in African-Americans than whites but did not differ in IDL or LDL (Figure 2, Second Row). Apo-C-III was lower in dense VLDL in African-Americans than whites, but did not differ by race in light VLDL, IDL or LDL (Figure 2, Third Row) ApoE content did not differ by race in any of the lipoproteins (Figure 2, Fourth Row).

**Table 2 Fasting lipids and apolipoproteins**

| Variable                  | African-Americans | Whites       | \( P \)-Value\(^2\) |
|---------------------------|-------------------|--------------|----------------------|
| Whole plasma – Chol (mg/dL) | 171 (160, 189)    | 184 (123, 217) | 0.968                |
| Whole plasma – TG (mg/dL)   | 56 (44, 82)       | 87 (65, 131)  | 0.038                |
| Whole plasma – HDL-C (mg/dL) | 58 (51, 74)       | 45 (38, 52)   | 0.014                |
| Whole plasma – LDL-C (mg/dL) | 85 (71, 103)      | 91 (61, 119)  | 0.527                |
| Whole plasma – ApoB (mg/dL) | 47 (35, 57)       | 62 (47, 72)   | 0.058                |
| Whole plasma – ApoCIII (mg/dL) | 10.06 (6.58, 14.78) | 11.06 (8.32, 13.75) | 0.843                |
| Light VLDL-TG (mg/dL)       | 15.8 (6.8, 24.1)  | 35.9 (19.5, 65.7) | 0.014                |
| Light VLDL-apoB (mg/dL)     | 1.52 (0.66, 3.29) | 2.76 (1.59, 6.30) | 0.063                |
| Light VLDL-apoCIII (mg/dL)  | 0.87 (0.53, 1.55) | 1.50 (0.76, 2.71) | 0.304                |
| Light VLDL-apoE (mg/dL)     | 0.63 (0.35, 1.43) | 0.38 (0.30, 0.82) | 0.192                |
| Dense VLDL-TG (mg/dL)       | 7.0 (5.5, 21.0)   | 22.5 (12.5, 28.7) | 0.011                |
| Dense VLDL-apoB (mg/dL)     | 0.56 (0.21, 1.02) | 1.22 (0.79, 2.02) | 0.010                |
| Dense VLDL-apoCIII (mg/dL)  | 0.32 (0.18, 0.69) | 0.91 (0.75, 1.43) | 0.014                |
| Dense VLDL-apoE (mg/dL)     | 0.26 (0.06, 0.42) | 0.31 (0.12, 0.51) | 0.407                |
| IDL-TG (mg/dL)              | 7.9 (4.5, 11.9)   | 7.8 (6.2, 14.0) | 0.553                |
| IDL-apoB (mg/dL)            | 2.37 (1.51, 3.91) | 4.14 (1.29, 5.05) | 0.429                |
| IDL-apoCIII (mg/dL)         | 0.27 (0.13, 0.41) | 0.31 (0.18,0.75) | 0.527                |
| IDL-apoE (mg/dL)            | 0.37 (0.24, 0.49) | 0.35 (0.26, 0.59) | 0.752                |
| LDL-TG (mg/dL)              | 11.6 (10.6, 13.7) | 11.9 (8.4, 18.1) | 0.906                |
| LDL-apoB (mg/dL)            | 37.6 (29.3, 48.17) | 47.8 (39.1, 59.2) | 0.123                |
| LDL-apoCIII (mg/dL)         | 0.86 (0.48,1.70)  | 0.95 (0.46, 1.24) | 0.502                |
| LDL-apoE (mg/dL)            | 1.14 (0.87, 1.38) | 0.93 (0.62, 1.32) | 0.323                |

\(^{1}\)Data presented as median (25\(^{th}\%), 75\(^{th}\%).

\(^{2}\)Comparisons by Mann–Whitney U test.
Dietary intake and time were entered into every model in Tables 3 and 4 and always made a significant contribution (all P < 0.01). Therefore, “time” is not presented in each model, but its presence and significance is to be understood.

In Table 3, Race, SI, and VAT were examined in separate and combined models to determine their influence on TG levels in light and dense VLDL, IDL, and LDL.

Model A - Race
For light and dense VLDL, race was a significant determinant of the TG concentration (overall R^2 = 17% and 16% respectively, both P < 0.01). In contrast, race did not influence TG concentration in IDL or LDL (both overall R^2 = 2% and P ≥ 0.7).

Model B - Race and SI
For light and dense VLDL, with race and SI in the model, both were significant determinants of TG concentration; overall R^2 was 30% and 25% respectively (both P ≤ 0.05).

Neither race nor SI contributed significantly to the TG concentration of IDL or LDL; overall R^2 was 9% and 10% respectively.

Model C - Race and VAT
For light and dense VLDL, when race and VAT were the two independent variables, both were significant contributors to the TG content of light and dense VLDL. Importantly, the overall R^2 for these models were higher at 47% and 40% than for the preceding model to which the two independent variables were race and SI.

VAT was a predictor of the TG content of IDL. However, neither race nor VAT were determinants of the TG content of LDL.

Model D - Race, SI, and VAT
With race, SI, and VAT included as independent variables, VAT was a significant determinant of the TG content of light and dense VLDL lipoprotein, but SI was not. Furthermore, the overall R^2 for light and dense VLDL were 50% and 42%. These values are essentially unchanged from the model with only race and VAT.
The overall R² for each model is presented.

### Model A-Race, SΙ, VAT and apoB
ApoB concentration was a significant determinant of TG concentration of light and dense VLDL and LDL, but not LDL.

### Model B-Race, SΙ, VAT and apoC-III
ApoC-III was a significant determinant of the TG concentration of light and dense VLDL and IDL but not LDL.

### Model C-Race, SΙ, VAT and apoE
ApoE was a significant determinant of the TG concentration of light and dense VLDL and IDL but not LDL.

### Model D-Race, SΙ, VAT, apoB, apoC-III and apoE
In the combined models, race was not a significant contributor to the TG content of any of the lipoproteins. ApoB was a significant determinant of the TG content of only 2 lipoproteins: light VLDL and LDL. ApoC-III was the only apolipoprotein to be a significant determinant of the TG content of 3 lipoproteins, light and dense VLDL and IDL. ApoE was a significant determinant of TG content of only 2 lipoprotein particles: dense VLDL and LDL. The overall R² in these models was higher than for the models with only one apolipoprotein.

### Discussion
By analyzing the combined effect of race, insulin resistance, VAT and the apolipoproteins, we found that the most consistent determinants of the TG content of light and dense VLDL were VAT and apoC-III concentration. In the combined model, ApoB was a determinant of the TG content of light VLDL and apoE was a determinant of the TG content of dense VLDL. However, only apoC-III and VAT were significant determinants of the TG concentration in both light and dense VLDL. Therefore the absence of elevated triglyceride levels in African-American women despite the presence of insulin resistance may be explained, at least in part, by the combination of low VAT and low apoC-III concentrations.

By having SΙ and VAT in the same model, we were able to test in a combined population of African-American and white women the opposing effects of low VAT and insulin resistance on the TG concentration of VLDL particles. When VAT and insulin resistance were entered into separate models, each was an important determinant of TG concentration. However, when insulin resistance and VAT were entered into the same model, the effect of VAT on TG concentration in VLDL particles was significant but the effect of insulin resistance was not. In essence, the effects of insulin resistance and VAT in whites are difficult to separate because they are elevated in tandem and highly correlated. In African-Americans, insulin resistance and VAT are not elevated in tandem and therefore the opportunity to distinguish between the effects of each is provided. In short, low VAT in African-Americans appears to provide protection from the hypertriglyceridemia expected from insulin resistance.
Table 4 Random effects model to determine influence of apoproteins along with time\(^1\), race\(^2\), VAT and insulin resistance on TG levels

| Model | Variables | β-coef | SE  | P-val | Variables | β-coef | SE  | P-val | Variables | β-coef | SE  | P-val | Variables | β-coef | SE  | P-val |
|-------|-----------|--------|-----|-------|-----------|--------|-----|-------|-----------|--------|-----|-------|-----------|--------|-----|-------|
|       |           |        |     |       |           |        |     |       |           |        |     |       |           |        |     |       |
|       |           |        |     | R\(^2\)=61% |           |        |     | R\(^2\)=55% |           |        |     | R\(^2\)=27% |           |        |     | R\(^2\)=29% |
| A     | Race      | -0.52  | 0.25| 0.04  | Race      | -0.21  | 0.25| 0.41  | Race      | 0.04  | 0.21| 0.84  | Race      | 0.02  | 0.18| 0.90  |
|       | VAT       | 0.46   | 0.13| <0.01 | VAT       | 0.35   | 0.12| <0.01 | VAT       | 0.12  | 0.10| 0.23  | VAT       | -0.10 | 0.09| 0.28  |
|       | ApoB      | 0.16   | 0.05| <0.01 | ApoB      | 0.31   | 0.10| <0.01 | ApoB      | 0.06  | 0.03| 0.04  | ApoB      | 0.01  | 0.01| <0.01 |
| B     | Race      | -0.69  | 0.23| <0.01 | Race      | -0.13  | 0.23| 0.59  | Race      | 0.13  | 0.19| 0.48  | Race      | -0.09 | 0.20| 0.63  |
|       | VAT       | 0.47   | 0.12| <0.01 | VAT       | 0.37   | 0.11| <0.01 | VAT       | 0.10  | 0.09| 0.27  | VAT       | -0.03 | 0.10| 0.79  |
|       | ApoCIII   | 0.37   | 0.09| <0.01 | ApoCIII   | 0.61   | 0.15| <0.01 | ApoCIII   | 1.10  | 0.31| <0.01 | ApoCIII   | 0.07  | 0.12| 0.58  |
| C     | Race      | -0.88  | 0.26| <0.01 | Race      | -0.36  | 0.19| 0.05  | Race      | -0.09 | 0.19| 0.62  | Race      | -0.03 | 0.21| 0.90  |
|       | VAT       | 0.56   | 0.13| <0.01 | VAT       | 0.43   | 0.09| <0.01 | VAT       | 0.08  | 0.10| 0.42  | VAT       | <0.01 | 0.10| 0.94  |
|       | ApoE      | 0.57   | 0.21| <0.01 | ApoE      | 1.72   | 0.31| <0.01 | ApoE      | 1.03  | 0.36| <0.01 | ApoE      | -0.09 | 0.10| 0.39  |
| D     | Race      | -0.38  | 0.26| 0.15  | Race      | 0.01   | 0.19| 0.97  | Race      | 0.10  | 0.18| 0.58  | Race      | 0.12  | 0.19| 0.53  |
|       | VAT       | 0.36   | 0.13| <0.01 | VAT       | 0.33   | 0.09| <0.01 | VAT       | 0.04  | 0.09| 0.65  | VAT       | <0.01 | 0.04| 0.21  |
|       | ApoB      | 0.12   | 0.05| 0.02  | ApoB      | 0.13   | 0.08| 0.12  | ApoB      | 0.04  | 0.02| 0.13  | ApoB      | 0.02  | 0.01| <0.01 |
|       | ApoCIII   | 0.18   | 0.04| <0.01 | ApoCIII   | 0.27   | 0.05| <0.01 | ApoCIII   | 0.42  | 0.15| <0.01 | ApoCIII   | 0.02  | 0.03| 0.59  |
|       | ApoE      | 0.08   | 0.22| 0.72  | ApoE      | 1.07   | 0.33| <0.01 | ApoE      | 0.73  | 0.33| 0.03  | ApoE      | -0.13 | 0.09| 0.16  |

\(^1\)Time is significant in every model (P < 0.01).
\(^2\)Whites are the referent group.
\(^3\)SI: Insulin sensitivity index.
The overall R\(^2\) for each model is presented.
VAT is an important source of FFA for the liver. The reason low VAT may mitigate the hypertriglyceridemic effect of insulin resistance, could be related to the influence of VAT on hepatic fat content. Although in our investigation we did not measure of hepatic fat, the Dallas Heart Study has demonstrated that low VAT is highly correlated with low hepatic fat [29]. If VAT is low in African-Americans this could lead to a paucity of hepatic fat and it is reasonable to postulate that without sufficient substrate, insulin resistance cannot promote overproduction of VLDL-TG by the liver.

In addition to VAT, apoC-III has an important influence on TG concentrations. In our study apoC-III appeared to be the apolipoprotein with the widest impact on the TG concentration of VLDL. When all three apolipoproteins were entered into a single model, apoC-III was the only apoprotein to significantly influence the TG content of both light and dense VLDL. Therefore, the low apoC-III levels in African-Americans may contribute to the race difference in VLDL-TG content. From the perspective of cardiovascular disease, it is important to appreciate that the apoCIII content of LDL did not differ by race. LDL with apoC-III is the LDL subfraction which most strongly predicts cardiovascular disease [30,31]. Therefore, for African-Americans low apoC-III concentrations in VLDL particles may not translate into either low concentrations of apoC-III in LDL or cardioprotection.

At baseline, there was no race difference in the concentration of apoE in whole plasma, light or dense VLDL or LDL. Yet, in the full model after adjusting for race, insulin sensitivity, VAT, and all three apolipoproteins, apoE was significantly associated with TG concentration in only two lipid particles, dense VLDL and IDL. The lack of association between apoE and TG in light VLDL may be due in part to the fact that apoE facilitates the clearance of lipoproteins from circulation via the hepatic LDL-receptor [32].

The two major limitations of the study are the lack of kinetic data and the sample size. Without kinetic data we are unable to speculate whether TG concentrations are lower in African-Americans than whites because of decreased secretion or increased clearance or both. The sample size of 31 has the potential to predominantly create Type 2 errors, meaning that we are unable to detect race differences in certain variables which a larger comparison might have detected. Yet, a major strength of study is how similar the African-American and white women were in age, BMI, family history of diabetes and socioeconomic factors. An additional strength is that the women consumed a diet with the same distribution of nutrients for one week prior to the test meal. However, we did not collect data on the habitual diet of the participants. In addition, insulin resistance was measured while the participants were consuming their habitual diet while lipid parameters were obtained after 7 days on the standard diet. Nonetheless, we know of no similar investigation of race differences in TG levels which has placed the enrollees on a nutrient controlled diet for 1 week prior to determining the influence of apolipoproteins, insulin resistance and visceral fat on fasting and postprandial levels of TG. Further, the maintenance of the race difference in TG concentration in African-American and white women while on the same diet, suggests that the race difference in TG concentration is independent of diet as reported previously in the Omni Study [33].

Conclusion
It has long been a clinical conundrum as to why triglyceride (TG) levels are normal in African-Americans despite high rates of obesity, insulin resistance and cardiovascular disease. In the past research on race differences in TG concentration has focused mainly on the role of insulin resistance, our data strongly supports expanding the scope of study to include an evaluation of the influence of VAT and apoC-III. With more information from a wider scope of investigation, more effective paradigms can be developed to detect early cardiovascular risk in African-Americans may be identified. Overall, our investigation provides data on why not including TG levels in screening for cardiovascular disease is inappropriate in African-Americans. Our long term goal is the minimization of health disparities in cardiometabolic disease through better screening.

Competing interests
All of the authors declare they have no competing interests.

Authors’ contributions
AES and FMS designed the research. AES, JDF, ABC and MR conducted the research. AES, NY-C, MKT-R analyzed the data and performed the statistical analyses. AES, JDF, ABC, MKT-R, NY-C and FMS wrote the paper. All authors read and approved the final manuscript.

Acknowledgements
Anne E. Sumner and Madia Ricks are supported by the Intramural Program of NIDDK. Amber B. Courville is supported by the NIH Clinical Center. The grant was also funded by the NIH Bench to Bedside Program with a supplement to HL075286 (Frank M. Sacks).

Author details
1Diabetes, Endocrinology and Obesity Branch, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 2Harvard School of Public Health, Boston, MA, USA. 3Nutrition Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA. 4Tropical Medicine Research Institute, University of the West Indies, Kingston, Jamaica.

Received: 19 October 2013 Accepted: 4 December 2013 Published: 23 December 2013

References
1. Alberti KG, Eckel RH, Grundy SM, et al: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640–1645.
2. Lemieux I, Pasco A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000, 102:179–184.

3. Summer AE, Cowie CC: Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis 2008, 196:698–703.

4. Osei K: Metabolic syndrome in blacks: are the criteria right? Curr Opin Endo Met 2010, 10:199–208.

5. Ukegbu UI, Castillo DC, Knight MG, et al. Metabolic syndrome does not detect metabolic risk in African men living in the U.S. Diabetes Care 2011, 34:2297–2299.

6. Yu SS, Ramsey NL, Castillo DC, Ricks M, Summer AE. Triglyceride-based screening tests fail to recognize cardiometabolic disease in African immigrant and African-American men. Metab Syndr Relat Disord 2013, 11:15–20.

7. Summer AE, Harman JL, Buxbaum SG, et al. The triglyceride/high-density lipoprotein cholesterol ratio fails to predict insulin resistance in African-American women: an analysis of Jackson Heart Study. Metab Syndr Relat Disord 2010, 8:511–514.

8.Luc G, Favet C, Arveiler D, et al. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur l'Infarctus du Myocarde. J Lipid Res 1996, 37:508–517.

9. Sacks FM, Alaupovic P, Moyer LA, et al. VLDL, apolipoproteins B, CII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000, 102:1895–1902.

10. Adeli M, Olufs son SQ, Taskinen MR, Booren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:1225–1236.

11. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444:881–887.

12. Chow CC, Pennal V, Cukow G, et al. Higher acute insulin response to glucose may determine greater free Fatty Acid clearance in African-American women. J Clin Endocrinol Metab 2011, 96:2456–2463.

13. Zheng C, Ikewaki K, Walsh BW, Sacks FM. Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat. J Lipid Res 2006, 47:1771–1779.

14. Alaupovic P. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins. Methods Enzymol 1996, 263:32–60.

15. Campos H, Perlov D, Khoob C, Sacks FM: Distinct patterns of lipoproteins with apoB defined by presence of apoC- or apoE in hypercholesterolemia and hypertriglyceridemia. J Lipid Res 2001, 42:1239–1249.

16. Zheng C, Khoob C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 2007, 48:1190–1203.

17. Olavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995, 15:963–971.

18. Zheng C, Khoob C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010, 121:1722–1734.

19. Altomonte J, Cong L, Habararan S, et al: FoxO1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004, 114:1493–1503.

20. Dallinga-Thie GM, Groenendijk M, Blom RN, De Bruin TW, De Kant E. Genetic heterogeneity in the apolipoprotein C-III promoter and effects of insulin. J Lipid Res 2001, 42:1450–1456.

21. Li WW, Dannerman MA, Smith JD, Metzger S, Breslow JS, Jeffer T: Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995, 96:2601–2605.

22. Summer AE, Luercio MF, Frempong BA, et al: Validity of the reduced-sample insulin modified frequently-sampled intravenous glucose tolerance test using the nonlinear regression approach. Metabolism 2009, 58:220–225.

23. Boston RC, Stefanovski D, Moate PJ, Summer AE, Watanabe RM, Bergman RN. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 2003, 5:1003–1015.